{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:26:44Z","timestamp":1790659604501,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>The phase IV Fasenra Safety Trial in India (FAST) assessed the safety and effectiveness of benralizumab for a period of 24\u202fweeks in adult Indian patients with severe eosinophilic asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase IV, single-arm, multicenter, prospective, interventional study (NCT05384938) included benralizumab-na\u00efve adult patients (18\u201375\u202fyears) with a physician-confirmed diagnosis of severe asthma with an eosinophilic phenotype. Patients received 30\u202fmg of benralizumab subcutaneously once every 4\u202fweeks for the first three doses and then 30\u202fmg once every 8\u202fweeks thereafter as part of routine clinical care. The primary outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs), and serious TEAEs, along with the nature, incidence, and severity of AEs, including unexpected adverse drug reactions and AEs leading to treatment discontinuation or dose modifications. The secondary outcomes included time to first asthma exacerbation, annualized exacerbation rate, treatment outcome, and changes in absolute eosinophil count.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 155 patients screened, 138 (89.0%) who received at least one dose of benralizumab were included in the safety and effectiveness analysis. At baseline, the median number of asthma exacerbation events per year was 2.0, and the median absolute eosinophil count was 375.0 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (range: 70.0\u20137352.8). Overall, 31.2% of the patients (43) experienced TEAEs; the most common TEAEs were pyrexia (16.7%), dyspnea (5.1%), productive cough (4.4%), cough (2.9%), and nasopharyngitis (2.2%). Serious TEAEs were reported in 5 (3.6%) patients and included dyspnea and productive cough (reported in 4 patients each), pyrexia (3), and constipation, H1N1 influenza, and back pain (1 each). No TEAEs leading to study drug discontinuation or death were reported. Nineteen (13.8%) patients experienced asthma exacerbation during the 24\u202fweeks, with a median (range) time to first exacerbation event of 100.0 (41\u2013184) days. A total of 61.5% of the patients (83\/135) had well-controlled asthma, while 33.3% (45\/135) had partly controlled asthma. A statistically significant decrease was observed in the mean asthma exacerbation events per year (from baseline to Week 24; 2.0 vs. 0;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.0001) and peripheral blood eosinophil counts (from baseline to Weeks 4, 16, and 24;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this prospective, single-arm, multicenter, phase IV study in Indian patients with severe eosinophilic asthma demonstrated that benralizumab showed an acceptable and expected safety profile with consistent efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT05384938<\/jats:ext-link>\n                      , identifier NCT05384938.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1706737","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:14:37Z","timestamp":1776680077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and effectiveness of benralizumab in Indian patients with severe eosinophilic asthma: results from the FAST study"],"prefix":"10.3389","volume":"13","author":[{"given":"Deepak","family":"Talwar","sequence":"first","affiliation":[{"name":"Metro Hospitals and Heart Institute","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Nagarjuna","family":"Maturu","sequence":"additional","affiliation":[{"name":"Yashodha Hospital","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti L.","family":"Meshram","sequence":"additional","affiliation":[{"name":"Grant Government Medical College and Sir JJ Group of Hospital","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Mittal","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Science","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janipalli Venkata","family":"Praveen","sequence":"additional","affiliation":[{"name":"King George Hospital, Government Hospital for Chest and Communicable Diseases, Andhra Medical College","place":["Visakhapatnam, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randeep","family":"Guleria","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Science","place":["New Delhi, India"]},{"name":"Medanta\u2014The Medicity","place":["Gurugram, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Asthma Bhawan","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Fortis Hospital","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Kumar","family":"Verma","sequence":"additional","affiliation":[{"name":"King George's Medical University","place":["Lucknow, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Mohan","sequence":"additional","affiliation":[{"name":"Narayana Hrudayalaya Institute of Medical Sciences","place":["Bengaluru, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Narasimhan","sequence":"additional","affiliation":[{"name":"Apollo Hospital","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Yatharth Super Speciality Hospitals","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Yatharth Super Speciality Hospitals","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[{"name":"VMMC and Safdarjung Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal","family":"Parakh","sequence":"additional","affiliation":[{"name":"Sir Ganga Ram Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Momi","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharma India Ltd.","place":["Bengaluru, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/JAA.S178927","article-title":"Approaches to the assessment of severe asthma: barriers and strategies","volume":"12","author":"Majellano","year":"2019","journal-title":"J Asthma Allergy"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/lungindia.lungindia_271_22","article-title":"Biomarkers in severe asthma: identifying the treatable trait","volume":"40","author":"Gvalani","year":"2023","journal-title":"Lung India"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4168\/aair.2024.16.5.462","article-title":"Update on inflammatory biomarkers for defining asthma phenotype","volume":"16","author":"Sim","year":"2024","journal-title":"Allergy, Asthma Immunol Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/biomedicines9111684","article-title":"Characterization of T2-low and T2-high asthma phenotypes in real-life","volume":"9","author":"Ricciardolo","year":"2021","journal-title":"Biomedicine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"00309","DOI":"10.1183\/23120541.00309-2020","article-title":"Identification and treatment of T2-low asthma in the era of biologics","volume":"7","author":"Kyriakopoulos","year":"2021","journal-title":"ERJ Open Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1183\/13993003.congress-2020.2236","article-title":"Real prevalence of severe asthma in developing countries\u2014is the diagnosis correct?","volume":"56","author":"Chopra","year":"2020","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/lungindia.lungindia_582_21","article-title":"A retrospective observational study on pheno-endotypes of severe asthma among adults attending asthma clinic in a tertiary care Centre in India","volume":"39","author":"Talwar","year":"2022","journal-title":"Lung India"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4103\/lungindia.lungindia_502_18","article-title":"Inflammatory phenotypes of severe asthma in India","volume":"36","author":"Dasgupta","year":"2019","journal-title":"Lung India"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"00528","DOI":"10.1183\/23120541.00528-2021","article-title":"Prevalence, time trends and treatment practices of asthma in India: the global asthma network study","volume":"8","author":"Singh","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref11","first-page":"286","article-title":"Difficult-to-treat and severe asthma: management strategies","volume":"103","author":"Narasimhan","year":"2021","journal-title":"Am Fam Physician"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e005748","DOI":"10.1136\/bmjopen-2014-005748","article-title":"Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study","volume":"5","author":"Talini","year":"2015","journal-title":"BMJ Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4103\/lungindia.lungindia_73_16","article-title":"Correlation of total serum immunoglobulin E level, sputum, and peripheral eosinophil count in assessing the clinical severity in bronchial asthma","volume":"34","author":"Kumar","year":"2017","journal-title":"Lung India"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.12932\/AP-200220-0771","article-title":"Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: results from a large tertiary care hospital","volume":"41","author":"Shantakumar","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13223-018-0241-1","article-title":"Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data","volume":"14","author":"Husereau","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12890-023-02383-x","article-title":"Peripheral blood eosinophilia in adult asthmatic patients and its association with the severity of asthma","volume":"23","author":"Solomon","year":"2023","journal-title":"BMC Pulm Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaip.2016.07.015","article-title":"Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study","volume":"5","author":"Zeiger","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref19","volume-title":"Global Strategy for Asthma Management and Prevention","year":"2024"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref22","year":"2019"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.12688\/f1000research.132704.1","article-title":"An early Indian experience with benralizumab\u2014a compendium on severe asthma cases: a case series","volume":"12","author":"Talwar","year":"2023","journal-title":"F1000Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JAA.S432695","article-title":"Real-world safety and effectiveness of Benralizumab in Japanese patients with severe asthma: A multicenter prospective observational study","volume":"17","author":"Yamaguchi","year":"2024","journal-title":"J Asthma Allergy"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab","volume":"43","author":"Jackson","year":"2020","journal-title":"Drug Saf"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2384173","DOI":"10.1080\/20018525.2024.2384173","article-title":"Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma","volume":"11","author":"Somekawa","year":"2024","journal-title":"Eur Clin Respir J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"107611","DOI":"10.1016\/j.rmed.2024.107611","article-title":"Benralizumab efficacy and safety in severe asthma: a randomized trial in Asia","volume":"229","author":"Lai","year":"2024","journal-title":"Respir Med"},{"key":"ref34","year":""},{"key":"ref35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.21037\/atm.2020.04.01","article-title":"Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study","volume":"8","author":"Izumo","year":"2020","journal-title":"Ann Transl Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"110444","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed Pharmacother"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1706737\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:14:38Z","timestamp":1776680078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1706737\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1706737"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1706737","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1706737"}}